Abacavir contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Abacavir}} {{CMG}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect")
 
mNo edit summary
 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Abacavir}}
{{Abacavir}}
{{CMG}}
{{CMG}}; {{AE}} {{AZ}}


==Contraindications==


ZIAGEN is contraindicated in patients with:


* Previously demonstrated hypersensitivity to abacavir or any other component of the products.
: ''NEVER restart ZIAGEN or any other abacavir-containing product following a [[hypersensitivity]] reaction to abacavir, regardless of [[HLA]]-B*5701 status.''
* Moderate or severe hepatic impairment [see Dosage and Administration].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ZIAGEN (ABACAVIR SULFATE) TABLET, FILM COATED ZIAGEN (ABACAVIR SULFATE) SOLUTION [VIIV HEALTHCARE COMPANY] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca73b519-015a-436d-aa3c-af53492825a1 | publisher =  | date =  | accessdate = 30 December 2013 }}</ref>


==References==
==References==

Latest revision as of 02:49, 5 January 2014

Abacavir
ZIAGEN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Contraindications

ZIAGEN is contraindicated in patients with:

  • Previously demonstrated hypersensitivity to abacavir or any other component of the products.
NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status.
  • Moderate or severe hepatic impairment [see Dosage and Administration].[1]

References

  1. "ZIAGEN (ABACAVIR SULFATE) TABLET, FILM COATED ZIAGEN (ABACAVIR SULFATE) SOLUTION [VIIV HEALTHCARE COMPANY]". Retrieved 30 December 2013.

Adapted from the FDA Package Insert.